Matrix metalloproteinase-1 and matrix metalloproteinase-12 gene polymorphisms and the outcome of coronary artery disease

Coronary Artery Disease

Volumn 22, Issue 6, 2011, Pages 388-393

  Jguirim Souissi, Imen ^a   Jelassi, Awatef ^a   Slimani, Afef ^a   Addad, Faouzi ^b   Hassine, Majed ^b   Hamda, Khaldoun Ben ^b   Najah, Mohamed ^a   Maatouk, Faouzi ^b   Rouis, Mustapha ^c   Slimane, Mohamed Naceur ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

coronary artery disease; haplotype; metalloproteinase; outcome; polymorphism

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE;

ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RESTENOSIS; RESTRICTION FRAGMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 12; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TUNISIA;

EID: 80051792892     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283478d40     Document Type: Article

References (24)

1. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
2. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-645. (Pubitemid 43139726)
3. Roger Lijnen H. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003/2004;33:275-281.
4. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, Calder PC, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004;35:1310-1315. (Pubitemid 38697449)
5. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, et al. Allelespecific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000;86:998-1003. (Pubitemid 30324313)
6. Rutter JL, Mitchell TI, Butticé G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and enhances transcription. Cancer Res 1998;58:5321-5325. (Pubitemid 28551108)
7. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999;59:4225-4227. (Pubitemid 29418732)
8. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-615. (Pubitemid 30453788)
9. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003;24:1668-1671. (Pubitemid 37174907)
10. Shin A, Cai Q, Shu XO, Gao YT, Zheng W. Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005;7:R506-R512.
11. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11:569-576. (Pubitemid 34257493)
12. Wallace AM, Sandford AJ. Genetic polymorphisms of matrix metalloproteinases: functional importance in the development of chronic obstructive pulmonary disease. Am J Pharmocogenomics 2002;2:167-175. (Pubitemid 35167863)
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
14. Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer. Matrix Biol 2000;19:175-177. (Pubitemid 30332441)
15. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-2509. (Pubitemid 29228279)
16. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex coronary plaques. Am J Cardiol 2005;95:90-92. (Pubitemid 40051116)
17. Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010;21:330-335.
18. Ghaderian SM, Najar RA, Tabatabaei Panah AS, Rezaie G, Rezaei Farimani A, Beigi Harchegani A, Azargashb E. Matrix metalloproteinase: investigation from gene to protein as effective factor in myocardial infarction. J Thromb Thrombolysis 2010;30:404-411.
19. Jguirim-Souissi I, Jelassi A, Addad F, Hassine M, Najah M, Ben Hamda K, et al. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity and outcome of coronary artery disease. Am J Cardiol 2007;100:23-27. (Pubitemid 46961894)
20. Cozzolino M, Biondi ML, Galassi A, Turri O, Brancaccio D, Gallieni M. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. Nephrol Dial Transplant 2009;24:2207-2212.
21. Fiotti N, Moretti ME, Bussani R, Altamura N, Zamolo F, Gerloni R, et al. Features of vulnerable plaques and clinical outcome of UA/NSTEMI: relationship with matrix metalloproteinase functional polymorphisms. Atherosclerosis 2011;215:153-159 (in press).
22. Nojiri T, Morita H, Imai Y, Maemura K, Ohno M, Ogasawara K, et al. Genetic variations of matrix metalloproteinase-1 and-3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003;92:181-186. (Pubitemid 37509980)
23. Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002;33:2408-2412.
24. Román-Garćia P, Coto E, Reguero JR, Cannata-Andiá JB, Lozano I, Avanzas P, et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population. Coron Artery Dis 2009;20:383-386.